Axon Enterprise, Inc (NASDAQ:AXON) Receives $721.57 Average Target Price from Analysts

Axon Enterprise, Inc (NASDAQ:AXON) has earned a consensus rating of “Moderate Buy” from the seventeen analysts that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $721.5714.

AXON has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, September 2nd. Piper Sandler boosted their price objective on shares of Axon Enterprise from $724.00 to $732.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research report on Wednesday, August 5th. Argus lifted their price target on shares of Axon Enterprise from $460.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Finally, Barclays lifted their price target on shares of Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon rebounded strongly after the initial selloff. Longer-term catalysts include continued demand for public-safety technology, recurring software revenue, international expansion and possible earnings-estimate upgrades. Axon Rebounded 6% Wednesday. Here’s What Could Drive the Stock Through 2026
• Positive Sentiment: Analysts maintain a generally constructive view, with Axon receiving an average “Moderate Buy” rating. Recent commentary also points to favorable earnings-estimate revisions that could support the shares if operating momentum continues. Axon Enterprise Given Average Rating of Moderate Buy Strength Seen in Axon
• Neutral Sentiment: Trading has been relatively flat as investors consolidate the sharp moves surrounding the debt transaction. Axon has also lagged the Nasdaq over the past year, despite analysts’ optimism about its long-term growth prospects. What’s Going On With Axon Enterprise Stock Friday? Is Axon Stock Underperforming the Nasdaq?
• Negative Sentiment: The convertible-notes offering triggered a sharp selloff because investors are concerned about future share dilution and the signal from raising capital while interest rates remain relevant. The notes carry no coupon, but conversion risk can still weigh on the stock’s near-term valuation. Axon Enterprise Stock Heads Into the Open After a 9.8 Percent Drop on Note Offering Axon’s Zero-Coupon Bet
• Negative Sentiment: Insider selling added another near-term confidence concern, while Axon’s high growth-oriented valuation leaves the shares sensitive to financing news, market performance and any slowdown in earnings growth. Axon Enterprise Shares Gap Down After Insider Selling

Axon Enterprise Trading Down 1.3%

NASDAQ:AXON opened at $447.76 on Thursday. Axon Enterprise has a 12-month low of $339.01 and a 12-month high of $792.16. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. The stock’s 50 day simple moving average is $547.50 and its 200-day simple moving average is $487.12. The firm has a market cap of $36.38 billion, a P/E ratio of 185.79, a PEG ratio of 8.43 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.84 by $0.04. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The firm had revenue of $904.39 million during the quarter, compared to the consensus estimate of $876.42 million. During the same period last year, the company earned $2.12 earnings per share. The company’s revenue for the quarter was up 35.3% on a year-over-year basis. Equities analysts anticipate that Axon Enterprise will post 2.12 EPS for the current year.

Insider Transactions at Axon Enterprise

In other news, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $508.99, for a total value of $5,089,900.00. Following the completion of the transaction, the chief executive officer owned 3,118,012 shares in the company, valued at $1,587,036,927.88. This trade represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 16,775 shares of Axon Enterprise stock in a transaction on Monday, August 31st. The stock was sold at an average price of $574.43, for a total value of $9,636,063.25. Following the transaction, the president directly owned 296,974 shares of the company’s stock, valued at $170,590,774.82. This trade represents a 5.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,397 shares of company stock valued at $38,160,884 in the last three months. 4.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Axon Enterprise

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its position in shares of Axon Enterprise by 4.3% in the second quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company’s stock valued at $4,672,432,000 after purchasing an additional 345,365 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Axon Enterprise by 8,432.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,537,957 shares of the biotechnology company’s stock worth $1,983,414,000 after purchasing an additional 3,496,493 shares during the last quarter. Geode Capital Management LLC lifted its stake in Axon Enterprise by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock valued at $1,265,657,000 after buying an additional 35,544 shares in the last quarter. Sands Capital Management LLC lifted its stake in Axon Enterprise by 11.6% in the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after buying an additional 167,095 shares in the last quarter. Finally, Nykredit A S acquired a new stake in Axon Enterprise during the 2nd quarter valued at $698,937,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and equipment for law enforcement, public safety and other government agencies. Its product portfolio includes TASER energy weapons, body-worn cameras, in-car cameras and related connected devices designed to support safer interactions, improve transparency and collect operational data.

The company also provides cloud-based software for managing digital evidence, conducting investigations, overseeing records and workflows, coordinating dispatch and supporting real-time public safety operations.